Newsroom

HOUSTON--(BUSINESS WIRE)--Zehl & Associates, the nationally acclaimed personal injury and wrongful death law firm, has been recognized for securing a record-setting $37.5 million wrongful death verdict against Oncor Electric Delivery Company following a deadly crash in Dallas. TopVerdict.com named the case one of the Top 50 Wrongful Death Verdicts in the United States for 2024. The crash occurred when an Oncor service truck slammed into the back of a disabled 18-wheeler parked partially on...

ATLANTA--(BUSINESS WIRE)--Coastal States Bank rings the NYSE Opening Bell in celebration of the IPO and official listing of its holding company, CoastalSouth Bancshares, Inc....

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference...

LYON, Francia--(BUSINESS WIRE)--Brenus Pharma, una empresa de biotecnología en fase clínica que se dedica a liberar el potencial del sistema inmunitario in vivo para combatir los tumores sólidos, ha anunciado que han concluido con éxito los primeros niveles de dosis en su primer estudio en humanos, que actualmente se encuentra en curso. Este ensayo multicéntrico y abierto (NCT06934538) es un estudio de fase Ia/Ib diseñado para evaluar el perfil de seguridad, tolerabilidad y la actividad clínica...

TORONTO--(BUSINESS WIRE)--Primaris Real Estate Investment Trust (“Primaris” or the “Trust”) (TSX: PMZ.UN) announced today that its Board of Trustees has declared a distribution of $0.07333 per unit for the month of January 2026, representing $0.88 per unit on an annualized basis. The distribution will be payable on February 17, 2026 to unitholders of record on January 30, 2026. About Primaris Real Estate Investment Trust Primaris is Canada’s only enclosed shopping centre focused REIT, with owne...

PASADENA, Calif.--(BUSINESS WIRE)--Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today the planned dates for its first quarter 2026 results and conference call. On Wednesday, January 28, 2026, after market close, Tetra Tech intends to announce its first quarter 2026 results. On Thursday, January 29, 2026, at 8:00 a.m. Pacific Time, Tetra Tech plans to host a conference call to...

MADISON, Wis.--(BUSINESS WIRE)--First Business Financial Services, Inc. (the “Company” or “First Business Bank”) (Nasdaq:FBIZ) invites participation in a conference call to discuss the Company’s financial and operating performance during its fourth quarter ended December 31, 2025. The conference call and webcast may contain forward-looking statements and other material information. Event: Earnings Conference Call – Fourth Quarter 2025 When: Friday, January 30, 2026 at 1:00 p.m. Central Time How...

SAN CARLOS, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute die vollständigen Ergebnisse der Phase-3-Studie HERIZON-GEA-01 bekannt. Die Studie untersuchte ZIIHERA® (Zanidatamab), einen HER2-gerichteten bispezifischen Antikörper, in Kombination mit einer Chemotherapie mit und ohne den PD-1-Inhibitor TEVIMBRA® (Tislelizumab) als Erstlinienbehandlung für ein HER2-positives (HER2+) lokal fortgeschr...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy los resultados completos del ensayo de Fase 3 HERIZON-GEA-01, que evaluó ZIIHERA® (zanidatamab), un anticuerpo biespecífico dirigido a HER2, en combinación con quimioterapia, con y sin el inhibidor de PD-1 TEVIMBRA® (tislelizumab), como tratamiento de primera línea para adenocarcinoma gástrico y esofágico HER2 positivo (HER2+) localmente avanzado o meta...